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Endothelial Lipase Plasma Levels Are Increased in Patients 
With Significant Carotid Artery Stenosis and History of 
Neurological Impairment
Monika Riederera, Matias Trbušićb, Vesna Degoricijab, c, Saša Franka, c
Abstract
Background: Endothelial lipase (EL) is a phospholipase expressed 
predominantly by vascular endothelial cells. The goal of the pres-
ent study was to examine whether EL plasma levels in patients with 
carotid artery stenosis differ between those with previous history of 
neurological impairment and those without neurological symptoms.
Methods: EL plasma levels were measured by a competitive ELI-
SA assay.
Results: EL plasma levels were significantly higher in the symp-
tomatic, compared with the asymptomatic group (mean 489.61 ± 
145 ng/ml (n = 31) vs. 388.39 ± 133 ng/ml (n = 24), t-test, P  = 
0.011).
Conclusions: We concluded that increased EL plasma levels reflect 
the patients’ overall susceptibility for cerebrovascular events.
Keywords: Atherosclerosis; Carotid artery stenosis; Endothelial 
lipase; Neurological impairment; Carotid endarterectomy
Introduction
Endothelial lipase (EL) is a member of the triglyceride lipase 
gene family, expressed by vascular endothelial cells and to a 
lesser extend by smooth muscle cells and macrophages [1]. 
EL lowers high-density lipoprotein (HDL) plasma levels, an 
independent risk factor for atherosclerosis [2]. EL plasma 
concentrations are increased in metabolic syndrome and as-
sociated with coronary atherosclerosis [3]. Most recently, 
using immunohistochemistry, we observed higher EL pro-
tein expression in symptomatic and unstable carotid plaques, 
compared with those from patients without neurological 
symptoms and with stable plaque phenotype [4]. The goal of 
the present study was to examine whether EL plasma levels 
in patients with carotid artery stenosis differ between those 
with previous history of neurological impairment and those 
without neurological symptoms.
Methods
Overall 66 patients with significant (70 - 99%) carotid ar-
tery stenosis, recruited and described as detailed elsewhere 
[4], were included in the study. Written informed consent 
from each patient was obtained prior to the enrollment in 
the study, which was performed according to Good Clini-
cal Practice and Helsinki Declaration principles. The study 
was approved by the local Ethics Committee, in accordance 
with institutional guidelines of the Sisters of Mercy Univer-
sity Hospital, Zagreb. Patients were grouped regarding his-
tory of previous neurological impairment into asymptomatic 
and symptomatic. The symptomatic group (ipsilateral stroke, 
transient ischemic attack or monocular blindness) comprised 
patients with symptoms unrelated to carotid artery stenosis 
(previous symptoms) and patients with symptoms referable 
to the respective carotid artery (recent symptoms). 
EL plasma protein levels were analyzed in 55 out of 66 
samples by a competitive ELISA assay [5]. In brief, 5 ng 
of an N-terminal peptide of human EL (Novus Biologicals, 
Littleton, CO) were immobilized on a 96-well EIA microtiter 
plate (Costar). After blocking nonspecific binding sites with 
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5% bovine serum albumine (BSA), a mixture comprising 50 
µl of 1:6 diluted plasma sample and 50 µl of an anti-EL anti-
body (Novus Biologicals) was applied to the wells and incu-
bated at room temperature for 3 h. After extensive washing, 
the plate was incubated with horseradish peroxidase (HRP)-
labeled goat-anti-rabbit secondary antibody. The amount of 
antibody bound to the immobilized N-terminal peptide of 
human EL was determined by the HRP-catalyzed dye devel-
opment using a colorless substrate (Pierce), on an ELISA-
reader. The standard curve was prepared by serial dilution 
of EL N-terminal peptide.  Cross-reactivity with other serum 
lipases, tested with purified preparations of lipoprotein lipase 
or hepatic lipase (kindly provided by Dr. G. Olivecrona, Uni-
versity of Umea, Sweden), was negligible. Plasma levels of 
high-sensitivity C-reactive protein hsCRP, IL-6 and HDL 
were measured as described [4].
Unpaired Student´s t-test and Mann-Whithney-U test 
were performed to assess differences among EL, hsCRP, 
IL-6 and HDL plasma concentrations between symptomatic 
and asymptomatic groups. The association between quanti-
tative data was evaluated using Spearman-rank correlation 
analysis. Data were analyzed using PASW 17.02 (IBM, Chi-
cago, IL, USA) software and all p values below 0.05 were 
considered significant.
 
Results
EL plasma levels were significantly higher in the symptom-
atic group compared with the asymptomatic group (mean 
489.61 ±145 ng/ml (n = 31) vs. 388.39 ± 133 ng/ml (n = 
24), t-test, P = 0.011) (Fig. 1). Patients with recent (n = 20) 
and previous (n = 11) symptoms had similar EL plasma 
levels. EL plasma levels were not statistically significantly 
correlated with the markers of inflammation (hsCRP, IL-6) 
or HDL plasma levels (Spearman correlation; r = 0.15 (P = 
0.28) for hsCRP; r = 0.02 (P = 0.88) for IL-6; r = 0.05 (P = 
0.72) for HDL); whereas hsCRP and IL-6 levels correlated 
significantly with each other (r = 0.61; P < 0.01). The hsCRP, 
IL-6 and HDL plasma levels were similar in symptomatic 
and asymptomatic patients.
Discussion
  
In contrast to plasma levels of inflammatory markers and 
HDL,  the  EL  plasma  levels  were  significantly  higher  in 
symptomatic patients. The lack of association between EL 
plasma levels and that of inflammatory markers might reflect 
the impact of gender and age, factors known to modulate 
plasma levels of inflammatory molecules [6, 7]. The lack of 
significant correlation between plasma EL and HDL levels 
might be due to medication [8-12] and is in line with a pre-
vious report [13]. We concluded that increased EL plasma 
levels,  independent  of  markers  of  inflammation  or  HDL 
plasma levels, reflect the patients’ overall susceptibility for 
cerebrovascular events. Whether EL is only a marker or an 
active causative factor for cerebrovascular events remains to 
Figure 1. EL protein levels were determined in plasma of 24 asymptomatic and 31 symptomatic patients by competitive ELISA. The 
boundaries of the box indicate the lower and upper quartiles, the horizontal line the median (370.6 vs. 452.6 ng/ml) and the error bars 
the 95% confidence interval. Outliers are indicated by ‘°’ and significance is denoted by ‘*’ (P = 0.011).
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be determined.
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